Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by King Luther Capital Management Corp

King Luther Capital Management Corp reduced its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 27.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 771,277 shares of the medical technology company's stock after selling 291,443 shares during the period. King Luther Capital Management Corp owned approximately 0.54% of Alphatec worth $4,288,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of ATEC. ProShare Advisors LLC grew its holdings in shares of Alphatec by 8.5% during the first quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company's stock worth $229,000 after buying an additional 1,304 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Alphatec by 1.2% in the first quarter. Vanguard Group Inc. now owns 5,458,847 shares of the medical technology company's stock valued at $75,278,000 after purchasing an additional 64,648 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Alphatec by 14.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,346 shares of the medical technology company's stock worth $364,000 after purchasing an additional 3,268 shares during the last quarter. Bayesian Capital Management LP lifted its holdings in shares of Alphatec by 5.6% during the first quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company's stock worth $372,000 after purchasing an additional 1,442 shares during the period. Finally, Comerica Bank grew its position in Alphatec by 64.8% in the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company's stock valued at $89,000 after buying an additional 2,534 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on ATEC shares. Barclays upped their price objective on shares of Alphatec from $19.00 to $20.00 and gave the stock an "overweight" rating in a research report on Tuesday. Wells Fargo & Company reduced their price objective on shares of Alphatec from $26.00 to $19.00 and set an "overweight" rating for the company in a research report on Thursday, August 1st. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Alphatec in a research report on Thursday, October 31st. Morgan Stanley cut Alphatec from an "overweight" rating to an "equal weight" rating in a report on Thursday, August 1st. Finally, Stifel Nicolaus decreased their price target on Alphatec from $19.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $17.11.

Alphatec Stock Performance

NASDAQ:ATEC opened at $10.06 on Friday. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The stock has a fifty day simple moving average of $6.62 and a 200-day simple moving average of $8.30.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.